Safety and effectiveness of the Vertex Pulmonary Embolectomy System in acute intermediate-risk pulmonary embolism: the SPIRARE II pivotal trial
EuroIntervention · 2026
DOI: 10.4244/eij-d-26-00454 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EuroIntervention, 2026. Verfasst von Sameh Sayfo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott & White Heart Hospital, Plano, TX, USA. Hauptthemen laut MEDLINE: Pulmonary Embolism, Embolectomy. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Percutaneous aspiration thrombectomy can rapidly reduce afterload in acute pulmonary embolism (PE), but catheter stiffness and instability may limit access and prevent effective right ventricle (RV) unloading. The Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) technology is designed to address current limitations of existing catheter-based systems by separating the flexibility necessary for safe navigation from the support that is essential for procedural control. AIMS: We aimed to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System for mechanical aspiration thrombectomy in acute intermediate-risk PE. METHODS: SPIRARE II was a prospective, single-arm, multicentre pivotal investigation conducted at 19 sites in the United States and Europe. Eligible patients had acute PE (≤14 days), a computed tomography angiography-assessed RV to left ventricle (RV/LV) ratio>0.9, and haemodynamic stability (systolic blood pressure ≥90 mmHg). Co-primary endpoints were composite major adverse events (MAE) within 48 hours and core laboratory-assessed RV/LV change from baseline to 48 hours. Prespecified secondary endpoints were collected immediately pre- and post-procedure in all patients including mean pulmonary artery pressure, total pulmonary vascular resistance, and cardiac index. RESULTS: In 123 patients, the 48-hour composite MAE rate was 2.4% (3/123), meeting the prespecified performance goal (one-sided p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Baylor Scott & White Heart Hospital, Plano, TX, USA.
- Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland.
- Staten Island University Hospital, Northwell Health, Staten Island, NY, USA.
- Division of Cardiology, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Department of Cardiology, Medical University of Vienna, Vienna, Austria.
- Division of Cardiovascular Disease, Hartford Healthcare Heart and Vascular Institute, Hartford, CT, USA.
Zitieren
APA
Sayfo, S., Stępniewski, J., Gallo, V., Rossi, J. S., Lang, I. M., Ingrassia, J., Rosenberg, R. D., Amin, R., Aggarwal, V., Jaber, W., Mahfoud, F., Kopec, G., Toma, C., & Ii Trial Investigators, O. B. O. T. S. (2026). Safety and effectiveness of the Vertex Pulmonary Embolectomy System in acute intermediate-risk pulmonary embolism: the SPIRARE II pivotal trial. EuroIntervention. https://doi.org/10.4244/eij-d-26-00454
Vancouver
Sayfo S, Stępniewski J, Gallo V, Rossi JS, Lang IM, Ingrassia J, et al. Safety and effectiveness of the Vertex Pulmonary Embolectomy System in acute intermediate-risk pulmonary embolism: the SPIRARE II pivotal trial. EuroIntervention. 2026. doi:10.4244/eij-d-26-00454
BibTeX
@article{Sayfo2026,
author = {Sayfo, Sameh and Stępniewski, Jakub and Gallo, Vincent and Rossi, Joseph S and Lang, Irene Marthe and Ingrassia, Joseph and Rosenberg, Russell D and Amin, Rohit and Aggarwal, Vikas and Jaber, Wissam and Mahfoud, Felix and Kopec, Grzegorz and Toma, Catalin and Ii Trial Investigators, On Behalf Of The Spirare},
title = {Safety and effectiveness of the Vertex Pulmonary Embolectomy System in acute intermediate-risk pulmonary embolism: the SPIRARE II pivotal trial},
journal = {EuroIntervention},
year = {2026},
doi = {10.4244/eij-d-26-00454}
}
EUVIMED